openPR Logo
Press release

Next generation antibody therapeutics market Size to Reach US$ 22.88 Billion by 2033 - Exclusive Report by DataM Intelligence

09-08-2025 03:21 PM CET | Health & Medicine

Press release from: DataM Intelligence 4 Market Research LLP

Next generation antibody therapeutics market - DataM Intelligence

Next generation antibody therapeutics market - DataM Intelligence

Next generation antibody therapeutics market reached US$ 9.09 Billion in 2024 from US$ 8.28 Billion in 2023 and is expected to reach US$ 22.88 Billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/next-generation-antibody-therapeutics-market?sg

Major M&A / big deals (2025)
✅ Bristol-Myers Squibb - BioNTech: BMS signed a landmark co-development / commercialization agreement with BioNTech for a promising bispecific oncology antibody (BNT327) - deal value up to ~$11 billion (includes upfront + milestones).

✅ BioNTech - CureVac (agreement/offer): BioNTech entered an all-stock acquisition agreement for CureVac valued at about $1.25B (announced mid-2025).

✅ AbbVie acquisition activity (2025): AbbVie moved to strengthen immunology/precision modalities via an acquisition of Capstan Therapeutics (reported ~$2.1B) - expanding in vivo delivery and cell/targeted modalities that complement antibody strategies.

Key product / regulatory milestones & launches (2025)

✅ New ADC approvals / launches in 2025 - multiple antibody-drug conjugates entered the clinic-to-market corridor in 2025; two new ADCs had been reported as newly approved by mid-2025 (regulatory momentum for ADC class). One cited ADC approval in 2025: AbbVie's telisotuzumab vedotin (Emrelis) received accelerated FDA approval for a NSCLC indication.

✅ BioNTech next-gen ADC (trastuzumab pamirtecan) - pivotal success: BioNTech reported pivotal study success for its trastuzumab-pamitrecan ADC in breast cancer (partnered with DualityBio) with positive progression-free survival results - driving regulatory discussions/filing plans. This result materially boosted sentiment and share performance.

Make an customized Enquiry for purchasing this Report @ https://www.datamintelligence.com/customize/next-generation-antibody-therapeutics-market?sg

Next generation antibody therapeutics Market Key Drivers:

➠ Advancements in Antibody Engineering
Novel platforms such as bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-engineered antibodies enhance specificity, efficacy, and safety, creating new therapeutic opportunities in oncology, autoimmune diseases, and infectious disorders.

➠ Rising Burden of Chronic and Rare Diseases
The increasing prevalence of cancer, autoimmune conditions, and rare genetic disorders is driving demand for targeted therapies with better outcomes compared to conventional treatments.

➠ Growing Biologics Pipeline
The expanding pipeline of monoclonal antibodies and next-generation formats in late-stage clinical trials reflects strong innovation and investment from pharmaceutical and biotech firms.

➠ Government and Private Sector Investments
Significant R&D funding, coupled with supportive regulatory pathways for breakthrough biologics, is fostering faster product development and commercialization.

➠ Shift Toward Personalized Medicine
Next-generation antibody therapeutics align with precision medicine approaches, offering customized treatment solutions based on genetic and molecular profiling of patients.

Market Segments:
By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered / Fc-fusion & Half-Life Extension, Antibody Fragments & Scaffolds and Others)
By Therapeutic Area (Oncology, Autoimmune & Inflammatory Diseases, Infectious Diseases, Ophthalmology, Rare Diseases and Others)
By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic and Research Institutes and Others)
By Region (North America, Europe, Asia-Pacific, South America and the Middle East & Africa)

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Next generation antibody therapeutics Market Geographical Share

The adoption of next-generation antibody therapeutics is accelerating worldwide, but the growth pattern varies across regions:

North America holds the largest share, driven by advanced healthcare infrastructure, strong funding for biopharmaceutical research, and high prevalence of chronic and autoimmune diseases. Regulatory support for innovative biologics and rapid clinical adoption of antibody-drug conjugates and bispecific antibodies further strengthen the region's dominance.

Europe follows closely, supported by rising collaborations between academic research centers and biopharma companies. Countries such as Germany, France, and the UK are focusing on personalized medicine approaches, creating demand for advanced antibody therapeutics.

Asia-Pacific is the fastest-growing region, with significant investments in biotechnology, rising patient populations, and government initiatives to improve biologics manufacturing capabilities. China, Japan, and South Korea are emerging hubs for clinical trials and large-scale production.

Latin America and Middle East & Africa are gradually expanding their market presence. Growth in these regions is fueled by improving access to biologic therapies, increasing healthcare spending, and partnerships with global drug manufacturers to expand treatment availability.

Market Key Players:
Key players are F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Biogen, ADC Therapeutics SA and Genmab A/S.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Next generation antibody therapeutics market Size to Reach US$ 22.88 Billion by 2033 - Exclusive Report by DataM Intelligence here

News-ID: 4174151 • Views:

More Releases from DataM Intelligence 4 Market Research LLP

United States Induction Motor Market 2031 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities
United States Induction Motor Market 2031 | Growth Drivers, Trends & Market Fore …
Induction Motor Market size was worth US$ 20.36 billion in 2023 and is estimated to reach US$ 33.66 billion by 2031, growing at a CAGR of 6.49% during the forecast period (2024-2031). Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/induction-motor-market?kb List of Top Key Player: ABB Ltd., Ametek, Emerson Electric, Siemens AG, Brook Crompton, Danaher Corporation, Johnson Electric Holdings, Regal Beloit, WEG Electric Corp.
Digital Therapeutics Market Set for Explosive Growth to USD 39.52 Billion by 2033, Led by North America's 42% Market Share | DataM Intelligence
Digital Therapeutics Market Set for Explosive Growth to USD 39.52 Billion by 203 …
The Global Digital Therapeutics Market size reached USD 6.84 billion in 2024 and is expected to reach USD 39.52 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2025-2033. Market growth is driven by the rising prevalence of chronic diseases like diabetes and mental health disorders, increasing smartphone penetration, and growing patient demand for personalized, app-based interventions. Advancements in AI and machine learning for behavior change, expanding
United States Contrast Media Injectors Market: Real-Time Market Trends & Competitive Landscape
United States Contrast Media Injectors Market: Real-Time Market Trends & Competi …
DataM Intelligence unveils its latest report on the "Contrast Media Injectors Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies
United States Real Time Location System (RTLS) Market Analysis 2026: Growth Drivers, Key Developments, Market Growth, Future Insights, Investment
United States Real Time Location System (RTLS) Market Analysis 2026: Growth Driv …
Real Time Location System (RTLS) Market is expected to grow at a CAGR of 18% during the forecasting period (2022-2029). Request a Premium Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://www.datamintelligence.com/download-sample/real-time-location-system-market?kb United States: Recent Industry Developments ✅ December 2025: Major healthcare systems expanded RTLS deployments to enhance patient tracking, asset utilization, and workflow efficiency. ✅ November 2025: Leading tech providers integrated AI‐driven analytics into RTLS platforms to deliver predictive

All 5 Releases


More Releases for ADC

ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments. Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion Key
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 Wo …
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology. New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates. New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313. Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg "2023
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment. On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023 Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends. This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering National Semiconductor Nippon Precision Circuits Inc Micro Analog systems Microchip Technology. TelCom Semiconductor, Inc Vishay Siliconix Texas